⌕
Ocular Therapeutix · OCUL · Nasdaq
Tenet 51 · Mixed
Compare
$6.02+0.17%At closeTenet 51 · Mixed
$6.02+0.01 (+0.17%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD

Ocular Therapeutix (OCUL) News

What's actually happening: chronological and provenance-stamped. News is context, not a signal.

Sources News publishers NewsHow we compute thisNot investment advice

The percentage on each card is OCUL's move today, from the quote feed. It is the same figure on every headline, not the move on that headline's own date.

● Seeking AlphaNov 17, 2026 · 09:22 ET
Ocular Therapeutix, Inc. (OCUL) Presents at UBS Global Biopharma Conference 2026 Transcript

Ocular Therapeutix, Inc. (OCUL) Presents at UBS Global Biopharma Conference 2026 Transcript…

OCUL +0.2% todayRead at source ↗
● Seeking AlphaNov 13, 2026 · 16:13 ET
Ocular: Maintaining 'Buy' On AXPAXLI NDA Submission Q4 2026 And DR Expansion Possibility

Maintaining a "Buy" on Ocular Therapeutix, supported by FDA alignment on the AXPAXLI wet-AMD filing and opportunities to extend dosing and indications. The company expects Q4 2026 SOL-R 52-week interim safety data and an…

OCUL +0.2% todayRead at source ↗
● Seeking AlphaNov 9, 2026 · 12:50 ET
Ocular Therapeutix, Inc. (OCUL) Q3 2026 Earnings Call Transcript

Ocular Therapeutix, Inc. (OCUL) Q3 2026 Earnings Call Transcript…

OCUL +0.2% todayRead at source ↗
● MarketBeatNov 9, 2026 · 12:17 ET
What Ocular Therapeutix (OCUL) Said on Its Q3 Earnings Call

Ocular Therapeutix NASDAQ: OCUL plans to submit a U.S. application in the fourth quarter of 2026 for AXPAXLI, its investigational treatment for wet age-related macular degeneration, executives said on the company's third…

OCUL +0.2% todayRead at source ↗
● Zacks Investment ResearchNov 9, 2026 · 09:41 ET
Ocular Therapeutix (OCUL) Reports Q3 Loss, Lags Revenue Estimates

Ocular Therapeutix (OCUL) came out with a quarterly loss of $0.42 per share versus the Zacks Consensus Estimate of a loss of $0.36. This compares to a loss of $0.37 per share a year ago.…

OCUL +0.2% todayRead at source ↗
● GlobeNewsWireNov 9, 2026 · 07:00 ETCOMPANY'S OWN WORDS
Ocular Therapeutix™ Reports Third Quarter 2026 Financial Results and Business Highlights

AXPAXLI™ NDA submission for wet AMD on track for 4Q 2026 following upcoming SOL-R interim Week 52 safety analysis Several FDA interactions, including most recent September 2026 Pre-NDA Meeting, reaffirm alignment on subm…

OCUL +0.2% todayRead at source ↗
● GlobeNewsWireNov 6, 2026 · 07:00 ETCOMPANY'S OWN WORDS
Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BEDFORD, Mass., Nov. 06, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular” or the “Company”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced…

OCUL +0.2% todayRead at source ↗
● Defense WorldNov 5, 2026 · 01:29 ET
Critical Analysis: Lyra Therapeutics (OTCMKTS:LYRA) and Ocular Therapeutix (NASDAQ:OCUL)

Ocular Therapeutix (NASDAQ: OCUL - Get Free Report) and Lyra Therapeutics (OTCMKTS:LYRA - Get Free Report) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses b…

OCUL +0.2% todayRead at source ↗
● GlobeNewsWireNov 2, 2026 · 07:00 ETCOMPANY'S OWN WORDS
Ocular Therapeutix™ to Report Third Quarter 2026 Financial Results on November 9, 2026

BEDFORD, Mass., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced that it plans to…

OCUL +0.2% todayRead at source ↗
● GlobeNewsWireOct 29, 2026 · 07:00 ETCOMPANY'S OWN WORDS
Ocular Therapeutix™ to Participate in November Investor and Scientific Conferences

BEDFORD, Mass., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced participation in…

OCUL +0.2% todayRead at source ↗
● Seeking AlphaOct 25, 2026 · 04:34 ET
Ocular Therapeutix: The Drug Won, The Stock Lost, And That's The Opportunity

Ocular Therapeutix is rated Buy (speculative) with a 12-month price target of $7.90, reflecting a lopsided risk/reward profile. AXPAXLI's strong Phase 3 SOL-1 results support a clear regulatory path, with NDA filing expe…

OCUL +0.2% todayRead at source ↗
● Seeking AlphaOct 23, 2026 · 19:57 ET
Ocular Therapeutix, Inc. (OCUL) Discusses Progress and Regulatory Update on AXPAXLI NDA Filing Transcript

Ocular Therapeutix, Inc. (OCUL) Discusses Progress and Regulatory Update on AXPAXLI NDA Filing Transcript…

OCUL +0.2% todayRead at source ↗
● MarketBeatOct 20, 2026 · 12:04 ET
Ocular Therapeutix Eyes Q4 FDA Filing for AXPAXLI After SOL-1 Win

Ocular Therapeutix NASDAQ: OCUL is preparing a fourth-quarter new drug application submission for AXPAXLI, its investigational maintenance treatment for wet age-related macular degeneration, following discussions with th…

OCUL +0.2% todayRead at source ↗
● GlobeNewsWireOct 9, 2026 · 07:00 ETCOMPANY'S OWN WORDS
Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular” or the “Company”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced that it has granted inducement equity awards to f…

OCUL +0.2% todayRead at source ↗
● GlobeNewsWireOct 1, 2026 · 07:00 ETCOMPANY'S OWN WORDS
Ocular Therapeutix™ to Participate in October Scientific and Investor Conferences

BEDFORD, Mass., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced participation in…

OCUL +0.2% todayRead at source ↗
● MarketBeatSep 22, 2026 · 23:02 ET
Ocular Therapeutix Eyes Q4 FDA Filing for AXPAXLI After SOL-1 Success

Ocular Therapeutix NASDAQ: OCUL said it remains on track to submit a U.S. marketing application for AXPAXLI in the fourth quarter of this year, following what Chief Executive Officer Pravin Dugel described as alignment w…

OCUL +0.2% todayRead at source ↗
● GlobeNewsWireSep 18, 2026 · 07:00 ETCOMPANY'S OWN WORDS
Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BEDFORD, Mass., Sept. 18, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular” or the “Company”), an integrated biopharmaceutical company committed to redefining the retina experience, today announce…

OCUL +0.2% todayRead at source ↗
● GlobeNewsWireSep 15, 2026 · 07:00 ETCOMPANY'S OWN WORDS
Ocular Therapeutix™ Announces Positive Pre-NDA Meeting with U.S. FDA for AXPAXLI™ in Wet AMD

Consistent with prior Type C Meeting, the Pre-NDA Meeting confirms Ocular's plan to submit AXPAXLI NDA based on SOL-1 Week 52 efficacy and safety, interim SOL-R safety, and confirmatory evidence AXPAXLI NDA submission fo…

OCUL +0.2% todayRead at source ↗
● GlobeNewsWireSep 1, 2026 · 07:00 ETCOMPANY'S OWN WORDS
Ocular Therapeutix™ to Participate in September and October Investor and Scientific Conferences

BEDFORD, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced participation i…

OCUL +0.2% todayRead at source ↗
● Defense WorldAug 28, 2026 · 04:12 ET
BlackRock Inc. Invests $190.28 Million in Ocular Therapeutix, Inc. $OCUL

BlackRock Inc. purchased a new stake in Ocular Therapeutix, Inc. (NASDAQ: OCUL) in a recent quarter, according to its most recent disclosure with the SEC. The fund purchased 19,376,555 shares of the biopharmaceutical com…

OCUL +0.2% todayRead at source ↗
● Seeking AlphaAug 18, 2026 · 19:02 ET
Ocular Therapeutix, Inc. (OCUL) Discusses Regulatory Progress and NDA Filing Plans for AXPAXLI Transcript

Ocular Therapeutix, Inc. (OCUL) Discusses Regulatory Progress and NDA Filing Plans for AXPAXLI Transcript…

OCUL +0.2% todayRead at source ↗

Kept in their own lane. A press release is the company talking, not reporting.

No upcoming events in the feeds.

NVDA29−0.4%
WDAY4−5.8%
BBW3−2.6%

Article counts from the last market-wide feed page, across every symbol we track and not just OCUL · day move from the quote feed. Equal counts are listed alphabetically, not ranked. Coverage ≠ importance.

The feed is purely chronological. No materiality ranking, no hidden sentiment score. Timestamps are publisher-reported and arrive with no timezone, so they are read and shown on the US market clock (ET); thumbnails come from each article's image field; day moves from the quote feed. Copies of the same story are collapsed on link or normalized headline, and a company's press release is kept over any syndicated copy of it; "company's own words" means the release title leads with the company's name and the wire names no other organisation first as its issuer; "earnings-tied" is a keyword match while a report date is upcoming. Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.